Metabolic PET Imaging as an early biomarker of cardiac toxicity following treatment with the tyrosine kinase inhibitor sunitinib

被引：0
|
作者：
Byrne, Annette T. [1 ]
机构：
[1] Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Lab Tumour Biol & Mol Imaging, Dublin 2, Ireland
来源：
ANGIOGENESIS | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
O-38
引用
收藏
页码：726 / 727
页数：2
相关论文
共 50 条
  • [21] Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era
    Gunnarsson, Niklas
    Stenke, Leif
    Hoglund, Martin
    Sandin, Fredrik
    Bjorkholm, Magnus
    Dreimane, Arta
    Lambe, Mats
    Markevarn, Berit
    Olsson-Stromberg, Ulla
    Richter, Johan
    Wadenvik, Hans
    Wallvik, Jonas
    Sjalander, Anders
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 683 - 688
  • [22] Acute motor neuropathy with quadriparesis following treatment with triple tyrosine kinase inhibitor, nintedanib
    Kunadu, Afua
    Alqalyoobi, Shehabaldin
    Frere, Robert C.
    Obi, Ogugua Ndili
    RESPIRATORY MEDICINE CASE REPORTS, 2021, 34
  • [23] Second Malignancies Following Treatment of Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era
    Gunnarsson, Niklas
    Leif, Stenke
    Hoglund, Martin
    Sandin, Fredrik
    Bjorkholm, Magnus
    Dreimane, Arta
    Lambe, Mats
    Markevarn, Berit
    Olsson-Stromberg, Ulla
    Richter, Johan
    Wadenvik, Hans
    Wallvik, Jonas
    Sjalander, Anders
    BLOOD, 2014, 124 (21)
  • [24] Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
    Serrano, Cesar
    Leal, Alessandro
    Kuang, Yanan
    Morgan, Jeffrey A.
    Barysauskas, Constance M.
    Phallen, Jillian
    Triplett, Olivia
    Marino-Enriquez, Adrian
    Wagner, Andrew J.
    Demetri, George D.
    Velculescu, Victor E.
    Paweletz, Cloud P.
    Fletcher, Jonathan A.
    George, Suzanne
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7287 - 7293
  • [25] Receptor Tyrosine Kinase Inhibitor Sunitinib as Novel Immunotherapy to Inhibit Myeloid-Derived Suppressor Cells for Treatment of Endometriosis
    He, Ying
    Hung, Sze Wan
    Liang, Bo
    Zhang, Ruizhe
    Gao, Yating
    Chu, Ching Yan
    Zhang, Tao
    Xu, Hui
    Chung, Jacqueline Pui Wah
    Wang, Chi Chiu
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [26] Tyrosine kinase inhibitor sunitinib targets the vasculature of clear cell renal cell carcinoma: a morphometrical study of treatment effect
    Chen, Lu
    Chen, Longwen
    Huang, Jie
    Xu, Danfeng
    Wang, Linhui
    Zhou, Ming
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 3571 - 3578
  • [27] Assessment of early response to tyrosine kinase inhibitor (erlotinib) in stage IIIB/IV NSCLC by PET/CT
    Benz, Matthias
    Walter, Franziska
    Garon, Edward
    Phelps, Michael
    Czernin, Johannes
    Allen-Auerbach, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52
  • [28] Nonclinical safety evaluation of sunitinib (SU11248; SUTENT), a novel multitargeted tyrosine kinase inhibitor for treatment of cancer
    Patyna, S.
    Heward, J. K.
    Evering, W.
    TOXICOLOGIC PATHOLOGY, 2007, 35 (01) : 188 - 188
  • [29] PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?
    Gerbaudo V.H.
    Kim C.K.
    Nuclear Medicine and Molecular Imaging, 2017, 51 (1) : 3 - 10
  • [30] Severe Hepatotoxicity Following Tyrosine Kinase Inhibitor Use for the Treatment of Chronic Myeloid Leukaemia in Pregnancy
    Narayanan, M.
    Fletcher, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 72 - 73
12345